Eye Area Surgery and Medical Aesthetic Services

Stem cells in aesthetics: product, evidence and safety questions

“Stem cells” does not define one product or a standard aesthetic procedure.

Editorial illustration; not evidence of a diagnosis, treatment outcome or individual plan.

On this page

Which product details must be clarified first?

Ask what the proposed procedure actually contains. Preparations from your own tissue and other sources are not equivalent. Processing, sterility, storage and intended use require separate explanation; a service name does not establish these facts. S1

Description	What it may mean	Explanation needed	Evidence question	Limitation
Cellular product	A preparation containing living cells	Source and processing	Human data for this product and purpose?	Evidence from another indication cannot be transferred S1
PRP	Platelet-rich plasma prepared from blood	Preparation and application	Human evidence for this method?	Not stem-cell therapy R1
Product described as exosomes	An extracellular-particle product	Actual contents and manufacture	Its own clinical data?	Not the same as stem cells S1

The table is not a treatment-selection tool. Results from similarly named preparations cannot be pooled indiscriminately; cells, tissue mixtures and exosomes need distinct evidence. S1 N1

Which options can be discussed?

Discussion may include no procedure, postponement and established options for the specific concern. Clarify the goal, how meaningful benefit would be measured and how much uncertainty remains. S1 C1

Laboratory findings, animal experiments or a short patient series do not establish lasting aesthetic benefit. Human studies need scrutiny of comparisons, follow-up, harms and financial interests; photographs and testimonials alone are insufficient. S1 N1

How should you prepare for consultation?

Ask for the exact product, source, processing, route, relevant authorization and human studies. Request clarification that any authorization concerns the right product, purpose and country. Share your medicines and medical history. S1 C2

Which risks must not be overlooked?

FDA describes serious harm reports with unapproved regenerative products, including infection, vision loss and tumor formation. This does not assign the same risk frequency to every product. US guidance does not replace Turkish authorization checks or verification of the clinic’s actual product. S1

Why do follow-up and records matter?

Record which product was used for which purpose and the follow-up plan. Monitor new symptoms and unwanted effects as well as benefit; automatically repeating sessions is not a substitute for evidence. S1 C2

What are the common questions?

Are my own cells risk-free?

No. An autologous source does not remove processing, contamination or administration risks. Origin alone is not a safety certificate. S1

Does approval for one disease cover aesthetics?

No. Authorization and evidence concern a product, purpose and jurisdiction. Use for another disease does not validate an aesthetic result. S1

Is a laboratory finding enough?

No. Cell behavior and meaningful lasting benefit in people are different questions. Appropriate human studies and harm monitoring are needed. S1 N1

Does FDA registration mean approval?

No. FDA explains that registration or a trial listing is not equivalent to approval. Documentation must match the product and purpose; this US distinction is not Turkish authorization. S1

Can I postpone a decision?

Yes. Waiting until uncertainties are clarified can be discussed. This text does not confirm that any product is stocked by the clinic or appropriate for you. S1 C1